THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Theophylline In Dextrose 5% In Plastic Container, and when can generic versions of Theophylline In Dextrose 5% In Plastic Container launch?
Theophylline In Dextrose 5% In Plastic Container is a drug marketed by Hospira Inc and is included in one NDA.
The generic ingredient in THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER is theophylline. There are thirty-six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theophylline In Dextrose 5% In Plastic Container
A generic version of THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER?
- What are the global sales for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER?
- What is Average Wholesale Price for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER?
Summary for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Clinical Trials: | 111 |
Formulation / Manufacturing: | see details |
DailyMed Link: | THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed |
![THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER drug patent expirations Drug patent expirations by year for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER](/p/graph/s/t/THEOPHYLLINE_IN_DEXTROSE_5%_IN_PLASTIC_CONTAINER-patent-expirations.png)
Recent Clinical Trials for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tanta University | N/A |
LG Chem | Phase 1 |
Medical College of Wisconsin | Phase 1/Phase 2 |
See all THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials